Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Functional Analyses of RUNX3 and CaMKIINα in Ovarian Cancer Cell Lines Reveal Tumor-Suppressive Functions for CaMKIINα and Dichotomous Roles for RUNX3 Transcript Variants.

Heinze K, Kritsch D, Mosig AS, Dürst M, Häfner N, Runnebaum IB.

Int J Mol Sci. 2018 Jan 15;19(1). pii: E253. doi: 10.3390/ijms19010253.

2.

Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.

Zhang L, Liu P, Li H, Xue F.

Mol Med Rep. 2013 May;7(5):1705-9. doi: 10.3892/mmr.2013.1371. Epub 2013 Mar 14.

PMID:
23504001
3.

MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer.

Paudel D, Zhou W, Ouyang Y, Dong S, Huang Q, Giri R, Wang J, Tong X.

Gene. 2016 Jul 15;586(1):48-55. doi: 10.1016/j.gene.2016.04.001. Epub 2016 Apr 2.

PMID:
27048832
4.

RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.

Häfner N, Steinbach D, Jansen L, Diebolder H, Dürst M, Runnebaum IB.

Int J Cancer. 2016 Jan 1;138(1):217-28. doi: 10.1002/ijc.29690. Epub 2015 Jul 28.

5.

RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.

Zhang S, Wei L, Zhang A, Zhang L, Yu H.

OMICS. 2009 Aug;13(4):307-11. doi: 10.1089/omi.2009.0030.

PMID:
19645591
6.

Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.

Kritsch D, Hoffmann F, Steinbach D, Jansen L, Mary Photini S, Gajda M, Mosig AS, Sonnemann J, Peters S, Melnikova M, Thomale J, Dürst M, Runnebaum IB, Häfner N.

Int J Cancer. 2017 Oct 15;141(8):1600-1614. doi: 10.1002/ijc.30860. Epub 2017 Jul 12.

7.

RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.

Barghout SH, Zepeda N, Vincent K, Azad AK, Xu Z, Yang C, Steed H, Postovit LM, Fu Y.

Gynecol Oncol. 2015 Sep;138(3):647-55. doi: 10.1016/j.ygyno.2015.07.009. Epub 2015 Jul 15.

PMID:
26186909
8.

Epigenetic downregulation of RUNX3 by DNA methylation induces docetaxel chemoresistance in human lung adenocarcinoma cells by activation of the AKT pathway.

Zheng Y, Wang R, Song HZ, Pan BZ, Zhang YW, Chen LB.

Int J Biochem Cell Biol. 2013 Nov;45(11):2369-78. doi: 10.1016/j.biocel.2013.07.013. Epub 2013 Jul 24.

PMID:
23892093
9.

Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer.

Chen W, Gao N, Shen Y, Cen JN.

J Gastroenterol Hepatol. 2010 Apr;25(4):823-31. doi: 10.1111/j.1440-1746.2009.06191.x.

PMID:
20492341
10.

RUNX3 is inactivated by promoter hypermethylation in malignant transformation of ovarian endometriosis.

Guo C, Ren F, Wang D, Li Y, Liu K, Liu S, Chen P.

Oncol Rep. 2014 Dec;32(6):2580-8. doi: 10.3892/or.2014.3524. Epub 2014 Oct 3.

PMID:
25333219
11.

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.

Ehlén A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brändstedt J, Uhlén M, Pontén F, Jirström K.

J Transl Med. 2010 Aug 20;8:78. doi: 10.1186/1479-5876-8-78.

12.

The role of the tumor suppressor RUNX3 in giant cell tumor of the bone.

Han YX, Liang DY.

Int J Oncol. 2012 Mar;40(3):673-8. doi: 10.3892/ijo.2011.1249. Epub 2011 Nov 4.

PMID:
22076387
13.

Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.

Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R.

Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16.

14.

Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma.

Kataoka J, Shiraha H, Horiguchi S, Sawahara H, Uchida D, Nagahara T, Iwamuro M, Morimoto H, Takeuchi Y, Kuwaki K, Onishi H, Nakamura S, Takaki A, Nouso K, Yagi T, Yamamoto K, Okada H.

Oncol Rep. 2016 May;35(5):2576-82. doi: 10.3892/or.2016.4681. Epub 2016 Mar 16.

15.

Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.

Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T.

Lung Cancer. 2007 Oct;58(1):131-8. Epub 2007 Jul 2.

PMID:
17606310
16.

RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway.

Li DJ, Shi M, Wang Z.

Thorac Cancer. 2016 Sep;7(5):570-580. doi: 10.1111/1759-7714.12370. Epub 2016 Jun 20.

17.

Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.

Jiang Y, Tong D, Lou G, Zhang Y, Geng J.

Pathobiology. 2008;75(4):244-51. doi: 10.1159/000132385. Epub 2008 Jun 26.

18.

Investigation of transcriptional gene silencing and mechanism induced by shRNAs targeted to RUNX3 in vitro.

Feng XZ, He XS, Zhuang YZ, Luo Q, Jiang JH, Yang S, Tang XF, Liu JL, Chen T.

World J Gastroenterol. 2008 May 21;14(19):3006-14.

19.

RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer.

Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S.

Cancer Res. 2006 Jul 1;66(13):6512-20.

20.

Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.

Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, Têtu B, Bairati I, Bachvarov D.

Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.

Supplemental Content

Support Center